Home/Filings/4/0001628280-24-004288
4//SEC Filing

DiBiase Mary 4

Accession 0001628280-24-004288

CIK 0001501697other

Filed

Feb 11, 7:00 PM ET

Accepted

Feb 12, 5:23 PM ET

Size

5.4 KB

Accession

0001628280-24-004288

Insider Transaction Report

Form 4
Period: 2024-02-12
DiBiase Mary
Chief Operating Officer
Transactions
  • Sale

    Common Stock

    2024-02-12$1.01/sh3,683$3,709307,161 total
Footnotes (2)
  • [F1]Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.98 to $1.04, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Issuer

X4 Pharmaceuticals, Inc

CIK 0001501697

Entity typeother

Related Parties

1
  • filerCIK 0001880179

Filing Metadata

Form type
4
Filed
Feb 11, 7:00 PM ET
Accepted
Feb 12, 5:23 PM ET
Size
5.4 KB